Lilly raises outlook for third time this year as Zepbound sales soar
The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.